Journals / Yeni Üroloji Dergisi / 2022 / Cilt: 17 - Sayı: 3

Systematic versus cognitive targeted biopsy: evaluation of parameters related to clinically significant prostate cancer and comparison of detection rates

Sistematik ve kognitif hedefe yönelik biyopsi: klinik olarak anlamlı prostat kanseri ile ilgili parametrelerinin değerlendirilmesi ve tespit oranlarının karşılaştırılması

Pages
187–195
Publication Date
2022-10-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CTB can be preferred in patients with larger lesions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aims to compare the clinically significant prostate cancer (csPCa) detection rates of cognitive targeted biopsy (CTB) and systematic biopsy (SB) and to reveal the factors affecting csPCa detection rates.Material and Methods: Patients diagnosed with localized prostate cancer between 2016-2019 were evaluated retrospectively.
📊
Key Findings & Data:We also studied whether there was a concordance between the localization of the lesion on MRI (magnetic resonance imaging) and the localization of the nodule detected on DRE.Results: Eighty patients were included in the study. csPCa was detected in 55 (68.7%) patients with SB, whereas CTB alone detected csPCa in 35 (43.7%) patients (p<0,01).
💡
Conclusion & Impact:CTB can be preferred in patients with larger lesions.
🔬Design:Research Article
📍Scope:2016-2019 Verileri
⚙️Variables:Prostat kanseri · prostat biyopsisi · manyetik rezonans görüntüleme

Abstract

Objective: This study aims to compare the clinically significant prostate cancer (csPCa) detection rates of cognitive targeted biopsy (CTB) and systematic biopsy (SB) and to reveal the factors affecting csPCa detection rates.Material and Methods: Patients diagnosed with localized prostate cancer between 2016-2019 were evaluated retrospectively. Patients who underwent SB and concomitant CTB were recorded. The number of cores taken from the index lesion in CTB, age, prostate-specific antigen (PSA) level, Gleason score, International Society of Urological Pathology (ISUP) grade, Prostate Imaging and Data Reporting System (PIRADS) score, the diameter of index lesion, and digital rectal examination (DRE) findings was recorded. We also studied whether there was a concordance between the localization of the lesion on MRI (magnetic resonance imaging) and the localization of the nodule detected on DRE.Results: Eighty patients were included in the study. csPCa was detected in 55 (68.7%) patients with SB, whereas CTB alone detected csPCa in 35 (43.7%) patients (p<0,01). SB missed 2 patients with csPCa, but 35% of the men with csPCa would be missed by CTB. Detection rates of csPCa in SB and CTB were significantly higher in patients with a concordance between DRE and mpMRI (p= 0.012 and p<0.01, respectively). In patients who had csPCa in CTB, significant differences were detected in the mean age, prostate volume, PSA, lesion diameter, number of cores, and PIRADS score (p=0.005, p=0.02, p=0.005, p=0.003, p=0.017, and p=0.002, respectively)Conclusion: SB maintains its importance in the diagnosis of csPCa. CTB can be preferred in patients with larger lesions.

Özet

Amaç: Bu çalışmanın amacı, kognitif hedefe yönelik biyopsi (KHB) ve sistematik biyopsinin (SB) klinik anlamlı prostat kanseri (kaPKa) tespit oranlarını karşılaştırmak ve kaPKa tespit oranlarını etkileyen faktörleri ortaya çıkarmaktır. Gereç ve Yöntemler: 2016-2019 yılları arasında lokalize prostat kanseri tanısı alan hastalar retrospektif olarak değerlendirildi. KHB ve SB yapılan hastalar kaydedildi. İndeks lezyondan alınan KHB kor sayısı, yaş, prostat spesifik antijen (PSA) seviyesi, gleason skoru, ISUP (International Society of Urological Pathology) derecesi, PIRADS (Prostate Imaging and Data Reporting System) skoru, indeks lezyonun büyüklüğü ve parmakla rektal muayene (PRM) bulguları kaydedildi. Ayrıca lezyonun magnetik rezonans görüntüleme (MRG)’ deki lokalizasyonu ile PRM ile tespit edilen nodülün lokalizasyonu arasında bir uyum olup olmadığı da araştırıldı.Bulgular: Seksen hasta çalışmaya dahil edildi. SB’li 55 (%68.7) hastada kaPKa saptanırken, tek başına KHB ile 35 (%43.7) hastada kaPKa saptandı (p<0.01). SB ile 2 kaPKa hastası atlanmasına karşın KHB ile kaPKa hastaların % 35’ine tanı konulamadı. SB ve KHB’de kaPKa tespit oranları, PRM ve mpMRG arasında bir uyum olan hastalarda anlamlı olarak daha yüksekti (sırasıyla p= 0.012 ve p<0.01). KHB’de kaPKa saptanan hastalarda ortalama yaş, prostat hacmi, PSA, lezyon çapı, kor sayısı ve (PGVRS) skoru açısından anlamlı farklılıklar saptandı ( sırasıyla p=0.005, p=0.02, p=0.005, p=0.003, p=0.017 ve p=0.002).Sonuç: SB, kaPKa tanısında önemini korumaktadır. Daha büyük lezyonları olan hastalarda KHB tercih edilebilir.

🔖

Cite This Article

ERSÖZ, C., İLKTAÇ, A., KALKAN, S., KAYALI, Y., AKBULUT, H., TOPRAK, H., DOĞAN, B. (2022). Systematic versus cognitive targeted biopsy: evaluation of parameters related to clinically significant prostate cancer and comparison of detection rates. Yeni Üroloji Dergisi, Cilt: 17 - Sayı: 3, 187–195. https://ajindex.com/articles/711104

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:359-86. DOI: 10.1002/ijc.29210. Cremers RGHM, Karim-Kos HE, Houterman S, et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer. 2010; 46:2077–87. DOI: 10.1016/j.ejca.2010.03.040. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021; 79:243–62. DOI: 10.1016/j.eururo.2020.09.042. Heijmink SWTPJ, van Moerkerk H, Kiemeney LALM, et al. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol. 2006; 16:927–38. DOI: 10.1007/s00330-005-0035-y. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. Lancet. 2017; 389:815–22. DOI: 10.1016/S0140-6736(16)32401-1.
  2. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018; 378:1767–77. DOI: 10.1056/NEJMoa1801993.
  3. Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: A systematic review. Eur Urol. 2013; 63:125–40. DOI: 10.1016/j.eururo.2012.06.004. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016; 69:16–40. DOI: 10.1016/j.eururo.2015.08.052. Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: A systematic review and meta-analysis. Eur Urol. 2015; 68:438–50. DOI: 10.1016/j.eururo.2014.11.037. Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: Multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology. 2013; 268:461–9. DOI: 10.1148/radiol.13121501. Bratan F, Niaf E, Melodelima C, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: A prospective study. Eur Radiol. 2013; 23:2019–29. DOI: 10.1007/s00330-013-2795-0